Evidence map›Paper›PMID 42232502›Full record

ArticlebioRxiv : the preprint server for biology2026

Molecular insights into protein disulfide isomerase antagonism by punicalagin.

Osamede C Owegie, Quinn P Kennedy, Ivan Hancco Zirena, Oren Levy, Pavel Davizon-Castillo, Moua Yang

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Osamede C OwegieBloodworks Northwest Research Institute, Seattle, WA 98102, USA.ORCID 0009-0009-2320-9863
Quinn P KennedyBloodworks Northwest Research Institute, Seattle, WA 98102, USA.ORCID 0009-0003-2074-6176
Ivan Hancco ZirenaCentro de Investigación en Medicina de Altura (CIMA), Facultad de Medicina Humana, Universidad de San Martín de Porres, Lima 15001, Peru.ORCID 0000-0002-4491-1004
Oren LevyDepartment of Anesthesia, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Pavel Davizon-CastilloBen Towne Center for Childhood Cancer Research and the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA 98102, USA.ORCID 0009-0009-5540-5041
Moua YangBloodworks Northwest Research Institute, Seattle, WA 98102, USA.ORCID 0000-0001-6340-457X

Funding

Inflammation-associated Autophagy DysfunctionR00HL177831 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI Pavel Davizon-Castillo · 2025 to 2026
$934k
Oxidative Cysteine Modification by Thiol Isomerases in Sickle Cell DiseaseR00HL164888 · NHLBI · BLOODWORKS · PI Moua Yang · 2024 to 2026
$747k
NHLBI NIH HHS R00 HL164888NHLBI NIH HHS R00 HL177831
6 · The paper itself

Abstract

Punicalagin, an ellagic acid polyphenol from pomegranate, has been proposed as an antagonist of protein disulfide isomerase (PDI) and endoplasmic reticulum resident protein 57 (ERp57), thiol oxidoreductases that regulate protein folding and extracellular thrombotic signaling. Here, biochemical oxidase and reductase assays on PDI show that punicalagin inhibits both activities with micromolar potency, thereby extending earlier work that described only disulfide reductase inhibition. In parallel, thiol labeling of catalytic cysteines revealed no change in the redox state, supporting a noncovalent, allosteric mechanism of inhibition. Molecular docking and molecular dynamics simulations showed that punicalagin binds stably and preferentially to defined sites on the N terminal domains of PDI through extensive hydrogen bonding and van der Waals contacts, which is an alternative binding mode to previously reported C-terminal binding. Finally, artificial intelligence-driven network analysis identified PDI as a high-confidence target of punicalagin and related galloylated polyphenols, alongside additional signaling proteins. Together, these findings provide further mechanistic framework for punicalagin-mediated antagonism of PDI and highlight galloylated polyphenols as promising scaffolds for protein disulfide isomerase-targeted therapeutics.

Indexed as

galloylated polyphenoloxidaseprotein disulfide isomerasepunicalaginreductaseThiol isomerase

Identifiers

PMID42232502
PMCPMC13225279

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.